Patterson, J., Cleary, S., Norman, J. M., Van Zyl, H., Awine, T., Mayet, S., Kagina, B., Muloiwa, R., Hussey, G., & Silal, S. P. (2024). Modelling the Cost-Effectiveness of Hepatitis A in South Africa. Vaccines, 12(2), 116. DOI: 10.3390/vaccines12020116
Iqbal, H., Mehmood, B. F., Sohal, A., & Roytman, M. (2023). Hepatitis E infection: A review. World journal of virology, 12(5), 262–271. DOI: 10.5501/wjv.v12.i5.262
Patterson, J., Cleary, S., Silal, S. P., Hussey, G. D., Enoch, A., Korsman, S., Goddard, E., Setshedi, M., Spearman, W. C., Kagina, B. M., & Muloiwa, R. (2022). A retrospective study assessing the clinical outcomes and costs of acute hepatitis A in Cape Town, South Africa. BMC infectious diseases, 22(1), 45. DOI: 10.1186/s12879-021-06993-w
Yang, T., Liu, B., Yue, L., Xie, T., Li, H., Shao, M., Yang, R., Luo, F., Long, R., & Xie, Z. (2021). Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71. Vaccine, 39(29), 3952–3963. https://doi.org/10.1016/j.vaccine.DOI: 10.1016/j.vaccine.2021.05.058
Elbahrawy, A., Ibrahim, M. K., Eliwa, A., Alboraie, M., Madian, A., & Aly, H. H. (2021). Current situation of viral hepatitis in Egypt. Microbiology and immunology, 65(9), 352–372. DOI: 10.1111/1348-0421.12916
Mutsaerts, E. A. M. L., Nunes, M. C., Bhikha, S., Ikulinda, B. T., Jose, L., Koen, A., Moultrie, A., Grobbee, D. E., Klipstein-Grobusch, K., Weinberg, A., & Madhi, S. A. (2020). Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. Vaccine, 38(22), 3862–3868. DOI: 10.1016/j.vaccine.2020.03.045
Fahrni, O., Posfay-Barbe, K. M., & Wagner, N. (2020). Immunization Against Hepatitis A in Migrant Children: Three Vaccination Strategies, A Retrospective Study. The Pediatric infectious disease journal, 39(2), 164–169. DOI: 10.1097/INF.0000000000002526
Rothe, C., Boecken, G., & Ständiger Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin und Globale Gesundheit (DTG) (2020). Reiseimpfungen [Travel vaccinations]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63(1), 74–84. Rothe, C., Boecken, G., & Ständiger Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin und Globale Gesundheit (DTG) (2020). Reiseimpfungen [Travel vaccinations]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63(1), 74–84. DOI: 10.1007/s00103-019-03064-z
Saffar, F., Sellaoui, F., Hechaichi, A., Chelly, S., Bouguerra, H., Cherif, A., Talmoudi, K., Ben Hadj, M., Bahrini, A., Letaief, H., Bahri, O., Chahed, M. K., & Bouafif Ép Ben Alaya, N. (2022). Epidemiologic patterns of hepatitis A infection during the pre-vaccination era: A population-based survey in Tunisia in 2015. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 117, 162–168. https://doi.org/10.1016/j.ijid.2022.01.004
Ming, B. W., Li, L., Huang, H. N., Ma, J. J., Shi, C., Xu, X. H., ... & Ou, C. Q. (2024). The effectiveness of national expanded program on immunization with hepatitis A vaccines in the Chinese Mainland: interrupted time-series analysis. JMIR Public Health and Surveillance, 10(1), e53982. https://preprints.jmir.org/preprint/53982 PREPRINT
Wang, X., Xu, W., Hu, Y., Yao, H., Xu, L., Ma, M., ... & Wang, Y. (2023). Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children: 15 years follow-up and long-term prediction. Human Vaccines & Immunotherapeutics, 19(2), 2227549. https://doi.org/10.1080/21645515.2023.2227549
Van Damme, P., Pintó, R. M., Feng, Z., Cui, F., Gentile, A., & Shouval, D. (2023). Hepatitis A virus infection. Nature Reviews Disease Primers, 9(1), 51. (NOT OA)
Elbahrawy, A., Atalla, H., Alboraie, M., Alwassief, A., Madian, A., El Fayoumie, M., ... & Aly, H. H. (2023). Recent advances in protective vaccines against hepatitis viruses: A narrative review. Viruses, 15(1), 214..https://doi.org/10.3390/v15010214
Migueres, M., Lhomme, S., & Izopet, J. (2021). Hepatitis A: epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses, 13(10), 1900. https://doi.org/10.3390/v13101900
Morgeaux, S., Manniam, I., Le Tallec, D., Chagnaud, P., & Costanzo, A. (2024). Establishment of hepatitis A virus coating reagent batch 2 for in vitro potency assay of hepatitis A vaccines by ELISA. Pharmeuropa bio & scientific notes, 2024, 240-250.
Hofmeister, M. G., Yin, S., Nelson, N. P., Weng, M. K., & Gupta, N. (2023). Trends and opportunities: hepatitis A virus infection, seroprevalence, and vaccination coverage—United States, 1976-2020. Public Health Reports, 00333549231184007. https://doi.org/10.1177/0033354923118400
Walsh, N., Torres, J., & Curtis, S. (2022). Hepatitis A Childhood and Adolescent Vaccination: A Systematic Review of the Effectiveness, Immunogenicity, Impact, Safety and Cost Effectiveness of Pediatric Vaccines: Final Report to the World Health Organization Strategic Advisory Group of Experts on Immunization Working Group on Hepatitis A Vaccines. https://www.nitag-resource.org/sites/default/files/2022-12/sage_hepatitisa_wg_systematic_review_09mar22.pdf
Buti, M., Bonanni, P., Ladep, N., Papatheodoridis, G., Frühwein, M., James, C., ... & Van Damme, P. (2025). Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities. Expert Review of Vaccines, 24(1), 373-383. https://doi.org/10.1080/14760584.2025.2502030
Wasley, A., Fiore, A., & Bell, B. P. (2006). Hepatitis A in the era of vaccination. Epidemiologic reviews, 28(1), 101-111. https://doi.org/10.1093/epirev/mxj012
Ashur, Y., Adler, R., Rowe, M., & Shouval, D. (1999). Comparison of immunogenicity of two hepatitis A vaccines—VAQTA® and HAVRIX®—in young adults. Vaccine, 17(18), 2290-2296. (NOT OA)